allergic asthma
Information
- Disease name
- allergic asthma
- Disease ID
- DOID:9415
- Description
- "An extrinsic asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. The disease has_symptom coughing, has_symptom wheezing, has_symptom shortness of breath or has_symptom rapid breathing, and has_symptom chest tightness." [url:http\://www.aafa.org/display.cfm?id=8&sub=16, url:https\://www.ncbi.nlm.nih.gov/books/NBK526018/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05297760 | Active, not recruiting | Phase 1/Phase 2 | Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract | February 10, 2022 | June 30, 2025 |
| NCT04619017 | Active, not recruiting | Phase 1 | Airway Immune Response to Allergens (Use Lay Language Here) | October 28, 2021 | March 1, 2024 |
| NCT05186025 | Active, not recruiting | Tyrosine Allergoid Paediatric and Adult Study | November 6, 2020 | October 2026 | |
| NCT00283504 | Completed | Phase 4 | A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy | January 2006 | January 2009 |
| NCT00380926 | Completed | Phase 2/Phase 3 | Fish Oil and Asthma in House Dust Mite Allergy | April 2004 | November 2004 |
| NCT00396409 | Completed | Phase 3 | Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis | February 2006 | August 2008 |
| NCT00406965 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma | December 2006 | September 2007 |
| NCT00421018 | Completed | N/A | Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK) | November 2006 | April 2010 |
| NCT00434434 | Completed | Phase 2 | A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma | October 2007 | June 2009 |
| NCT00485576 | Completed | Phase 2 | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma | September 2007 | November 2008 |
| NCT00490425 | Completed | Phase 4 | Prevention of Asthma and Allergy by Probiotic Lactobacillus GG | October 2002 | October 2006 |
| NCT00492076 | Completed | Phase 4 | Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma | October 2006 | May 2008 |
| NCT00507039 | Completed | Safety and Repeatability of Bronchial Challenge With Grass-pollen | February 2007 | December 2009 | |
| NCT00515775 | Completed | Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children | September 2005 | October 2008 | |
| NCT00535028 | Completed | Phase 2 | A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) | January 2005 | May 2005 |
| NCT00535431 | Completed | Phase 2 | Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics | December 2005 | October 2006 |
| NCT00550797 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma | January 2008 | October 2008 |
| NCT00565591 | Completed | Phase 1 | Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI | November 2007 | February 2008 |
| NCT00581048 | Completed | N/A | Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics | December 2006 | October 2011 |
| NCT00652223 | Completed | Phase 1/Phase 2 | Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy | March 2005 | November 2005 |
| NCT00670930 | Completed | Phase 4 | Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists | April 2008 | November 2011 |
| NCT00736801 | Completed | N/A | Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma | September 2005 | April 2007 |
| NCT00813748 | Completed | Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing | March 2009 | January 2014 | |
| NCT00829179 | Completed | Phase 3 | Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma | October 2002 | July 2004 |
| NCT00980707 | Completed | Phase 4 | Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma | August 2009 | November 2010 |
| NCT00999466 | Completed | Phase 2 | The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen | October 2009 | December 2011 |
| NCT00781443 | Completed | Phase 2 | A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma | December 2008 | |
| NCT00214019 | Completed | N/A | The Effect of Salmeterol on Eosinophil (EOS) Function | November 2003 | January 2008 |
| NCT00267202 | Completed | Phase 4 | Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma | December 2005 | April 2008 |
| NCT01544348 | Completed | Phase 1 | A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL | January 2012 | June 2013 |
| NCT01612715 | Completed | Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma | January 29, 2014 | March 22, 2018 | |
| NCT01669681 | Completed | Cobra (Severe Asthma)Medical-economic | December 20, 2011 | December 16, 2016 | |
| NCT01699594 | Completed | N/A | Change in Airway Responsiveness After Allergen Exposure | October 2012 | May 2014 |
| NCT01703312 | Completed | Phase 1/Phase 2 | A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma | November 2012 | October 2013 |
| NCT01821716 | Completed | Phase 2 | Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract | March 2013 | January 2014 |
| NCT01976208 | Completed | Phase 2/Phase 3 | Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma | December 2010 | December 2015 |
| NCT02023151 | Completed | Phase 4 | Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils | February 2013 | August 2016 |
| NCT02096237 | Completed | N/A | Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study) | December 2013 | November 2014 |
| NCT02504528 | Completed | N/A | Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou | July 1, 2015 | February 1, 2018 |
| NCT02541331 | Completed | Phase 3 | Efficacy Of Bacterial Lysate In Asthmatic Children | July 2014 | June 2015 |
| NCT02648074 | Completed | N/A | Eosinophil Induced Remodelling in Asthma | March 2014 | January 2017 |
| NCT02764437 | Completed | AsthMatic Inflammation and Neurocircuitry Activation (MINA) | July 28, 2016 | March 31, 2020 | |
| NCT02908360 | Completed | Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis | July 10, 2015 | December 31, 2017 | |
| NCT02911688 | Completed | Phase 2 | Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure | September 2016 | February 13, 2019 |
| NCT03213184 | Completed | Children's Respiratory and Environmental Workgroup | December 26, 2017 | June 30, 2023 | |
| NCT03776773 | Completed | N/A | Impact of Pollution on Allergic Rhinitis and Sleep Quality: the POLLAR Study | April 8, 2019 | January 25, 2020 |
| NCT03850626 | Completed | Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients | September 9, 2018 | September 3, 2020 | |
| NCT03861910 | Completed | Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations | December 2014 | December 2021 | |
| NCT04259164 | Completed | Phase 3 | Anti-inflammatory Effects Glycopyrronium | September 10, 2020 | December 29, 2022 |
| NCT04389034 | Completed | Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels | April 22, 2020 | October 5, 2020 | |
| NCT04476433 | Completed | N/A | Intervention in Chronic Pediatric Patients and Their Families. | February 4, 2019 | December 30, 2023 |
| NCT04648813 | Completed | Phase 4 | Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses | November 13, 2020 | April 20, 2021 |
| NCT04663880 | Completed | N/A | Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma | August 30, 2016 | February 15, 2017 |
| NCT04673591 | Completed | Phase 2 | Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients | December 9, 2020 | January 12, 2022 |
| NCT04678063 | Completed | N/A | Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma | April 10, 2017 | July 11, 2017 |
| NCT04878237 | Completed | N/A | Kinetics of Nasal Cytokine Responses to Mechanical Stimulation | March 25, 2021 | May 31, 2021 |
| NCT05192720 | Completed | N/A | Andosan in Allergic and Asthma Patients | August 31, 2021 | February 28, 2023 |
| NCT05424523 | Completed | Effectiveness and Safety of Omalizumab in Children With Allergic Asthma. | February 25, 2021 | June 28, 2021 | |
| NCT05813470 | Completed | Phase 3 | Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma | January 18, 2021 | January 15, 2023 |
| NCT06267261 | Completed | N/A | Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber | June 7, 2021 | October 25, 2021 |
| NCT01125748 | Completed | Phase 4 | A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy | May 2010 | August 2013 |
| NCT01155700 | Completed | Phase 3 | Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) | June 2010 | February 2012 |
| NCT01318954 | Completed | The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis | January 2008 | June 2011 | |
| NCT01328886 | Completed | Phase 3 | Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children | March 2011 | December 2013 |
| NCT01353755 | Completed | Phase 3 | 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma | October 2009 | September 2014 |
| NCT01365533 | Completed | Phase 2 | A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma | December 2004 | July 2005 |
| NCT01392859 | Completed | Phase 2/Phase 3 | Characterization of the Role of Histamine in Children With Asthma | June 2011 | March 29, 2015 |
| NCT01479205 | Completed | Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy | July 2010 | September 2011 | |
| NCT01536522 | Enrolling by invitation | Early Phase 1 | Asthma Inflammation Research | January 2011 | June 2025 |
| NCT06151938 | Enrolling by invitation | Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis | November 21, 2023 | August 20, 2025 | |
| NCT06438757 | Not yet recruiting | Phase 2 | Trial of JYB1904 in Allergic Asthma | June 21, 2024 | October 31, 2025 |
| NCT05641272 | Not yet recruiting | Phase 2/Phase 3 | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | November 1, 2023 | December 1, 2026 |
| NCT05400811 | Not yet recruiting | Phase 3 | Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis | December 2022 | July 2025 |
| NCT04699604 | Recruiting | Phase 3 | A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) | April 28, 2021 | May 1, 2025 |
| NCT05008965 | Recruiting | Phase 2 | Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma | July 27, 2021 | June 2024 |
| NCT02767973 | Recruiting | N/A | To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility | May 2016 | May 2025 |
| NCT05749237 | Recruiting | N/A | The Impact of Breath Exercises by Telemedicine in Patients Aged 8-18 Years With a Diagnosis of Asthma | February 3, 2023 | August 30, 2023 |
| NCT03119714 | Terminated | Phase 2 | Pemirolast in Allergen Challenge (PEMAG) | November 2016 | February 2018 |
| NCT00622362 | Terminated | Phase 2 | Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract | January 2008 | February 2009 |
| NCT02214303 | Unknown status | The Role of Th9 Cells and Eosinophils Activity in Allergic Airway Diseases | April 2013 | December 2015 | |
| NCT04567212 | Unknown status | Gender Differences and SNPs in Asthmatic Patients | August 1, 2020 | December 30, 2021 | |
| NCT00208234 | Unknown status | Phase 4 | Effect of Xolair on Airway Hyperresponsiveness | January 2004 | September 2011 |
| NCT05191186 | Unknown status | Phase 3 | Documentation of Efficacy of Intralymphatic Allergen Immunotherapy | February 1, 2020 | December 2023 |
| NCT03388359 | Unknown status | N/A | Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma | June 1, 2017 | December 8, 2020 |
| NCT03431961 | Unknown status | N/A | Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment | March 7, 2018 | February 2019 |
| NCT03820154 | Unknown status | N/A | Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest | March 1, 2019 | July 30, 2019 |
| NCT04902989 | Unknown status | Environmental Pollutants and Their Effects on Respiratory Allergy | March 10, 2021 | August 10, 2022 | |
| NCT04109534 | Unknown status | N/A | Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma | October 1, 2019 | December 30, 2020 |
| NCT00710450 | Unknown status | Effect of Montelukast on Basophils, In-vitro | May 2008 | September 2011 | |
| NCT04264377 | Unknown status | Towards Targeting the ORigin of the Inflammatory Cascade in Allergic Asthma | February 7, 2020 | December 2022 | |
| NCT04352088 | Unknown status | Immune Response Features in Allergic Airway Diseases | May 1, 2019 | April 2024 | |
| NCT01776177 | Unknown status | The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy | September 2012 | August 2013 | |
| NCT04542902 | Unknown status | N/A | Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma | October 1, 2020 | October 1, 2023 |
| NCT02965612 | Unknown status | N/A | Specific Immunotherapy for Allergic Child | May 2015 | May 2017 |
| NCT04401631 | Withdrawn | Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation | November 2020 | December 2020 | |
| NCT01019291 | Withdrawn | N/A | Role of Indoor Pollutants on House Dust Mite Allergic Asthma | ||
| NCT03307278 | Withdrawn | N/A | House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance | November 30, 2017 | September 6, 2018 |
| NCT01144910 | Withdrawn | The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children | May 2011 | September 2017 | |
| NCT04442932 | Withdrawn | abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies | November 15, 2020 | March 15, 2021 |
- Disase is a (Disease Ontology)
- DOID:0080811
- Cross Reference ID (Disease Ontology)
- ICD10CM:J45
- Cross Reference ID (Disease Ontology)
- ICD9CM:493.0
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:195968006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0155877
- Exact Synonym (Disease Ontology)
- extrinsic asthma with acute exacerbation
- Exact Synonym (Disease Ontology)
- extrinsic asthma with status asthmaticus
- Disase Synonym (Disease Ontology)
- atopic asthma